DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at Guggenheim

Equities research analysts at Guggenheim started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a note issued to investors on Wednesday, MarketBeat reports. The firm set a “buy” rating and a $35.00 price target on the stock. Guggenheim’s target price points to a potential upside of 169.44% from the stock’s current price.

Several other equities research analysts have also weighed in on DBVT. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective (up previously from $16.00) on shares of DBV Technologies in a report on Wednesday, October 29th. Zacks Research upgraded shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of DBV Technologies in a research report on Monday. Finally, Wall Street Zen raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Friday, November 28th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $20.81.

DBV Technologies Price Performance

NASDAQ:DBVT opened at $12.99 on Wednesday. The company has a market capitalization of $467.20 million, a P/E ratio of -2.51 and a beta of -1.10. The business has a fifty day simple moving average of $13.87 and a two-hundred day simple moving average of $11.05. DBV Technologies has a 1 year low of $2.74 and a 1 year high of $18.00.

Institutional Investors Weigh In On DBV Technologies

A number of institutional investors and hedge funds have recently modified their holdings of the company. Nan Fung Trinity HK Ltd. purchased a new position in DBV Technologies during the second quarter valued at approximately $340,000. Adage Capital Partners GP L.L.C. purchased a new stake in DBV Technologies in the 2nd quarter worth approximately $9,659,000. MPM Bioimpact LLC bought a new position in DBV Technologies in the 2nd quarter valued at $9,649,000. Octagon Capital Advisors LP purchased a new position in shares of DBV Technologies during the 2nd quarter valued at $9,315,000. Finally, Millennium Management LLC grew its position in shares of DBV Technologies by 26.1% during the 3rd quarter. Millennium Management LLC now owns 337,863 shares of the company’s stock valued at $3,379,000 after purchasing an additional 69,849 shares in the last quarter. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.